Cas:1538-09-6 Penicillin G benzathine manufacturer & supplier

Chemical Name:Penicillin G benzathine

CAS.NO:1538-09-6

Synonyms:leomypen;neolin;dibencil;4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-, (2S,5R,6R)-, compd. with N,N-bis(phenylmethyl)-1,2-ethanediamine (2:1);benzathine benzylpenicillin;(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid – N,N’-dibenzylethane-1,2-diamine (2:1);benzapen;moldamin;N,N’-Dibenzylethylenedi amine bis[benzylpenicillin];Megacillin;pendepon;DBED-penicillin;Penicillin G N,N’-dibenzylethylenediamine salt;[2S-(2a,5a,6b)]-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid compd with N,N’-bis(phenylmethyl)-1,2-ethanediamine (2:1);cillenta;N,N’-Dibenzyl-1,2-ethanediaminium bis{(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate};penadur;Benzathine Penicillin G;bicillin;longicil

Molecular Formula:C₄₈H₅₆N₆O₈S₂

Molecular Weight:909.124

HS Code:

Physical and Chemical Properties:

Melting point:123-124ºC

Boiling point:663.3ºCat 760 mmHg

Density:N/A

Index of Refraction:

PSA:248.08000

Exact Mass:908.360107

LogP:5.72700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like leomypen chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,longicil physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,neolin Use and application,leomypen technical grade,usp/ep/jp grade.

Related News: The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk. Penicillin G benzathine manufacturer The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk. Penicillin G benzathine supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. Penicillin G benzathine vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. Penicillin G benzathine factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.